April 24, 2015

Sandoz on Friday announced the launch of levoleucovorin injection ready-to-use single use vial, a generic version of Fusilev, which is marketed by Spectrum Pharmaceuticals. 

April 17, 2015

IMS Health is getting ready to launch a consumer version of its AppScript app, according to a MedCityNews report. 

April 14, 2015

Total dollars spent on prescriptions in the U.S. were up 13.1%.

April 9, 2015

Walgreens Boots Alliance on Thursday posted solid same-store sales numbers, driving U.S. sales up 7.4% to $21 billion, but has targeted 200 store closures in a cost-saving initiative. 

March 13, 2015

“Drugs don’t work in patients who don’t take them.”

March 10, 2015

Actavis expanded its portfolio of topicals with the launch of a generic corticosteroid.

March 10, 2015

ANI Pharmaceuticals acquired the approved abbreviated new drug application for flecainide acetate tablets USP in 50-mg, 100-mg and 150-mg dosage strengths.

February 9, 2015

Mylan Inc. and its subsidiary Mylan Pharmaceuticals are being sued by Bayer Healthcare, Bayer Healthcare Pharmaceuticals and Onyx Pharamceuticals in relation to the filing of an abbreviated new drug application for sorafenib tablets, the generic version of Nexavar. 

 

February 5, 2015

Generic drug prices are going up. Spurred by market opportunities, short-term market exclusivity for some newly launched single-source generics and rising costs for manufacturing, quality control and raw materials, me-too drug manufacturers have escalated a series of price hikes, some of them significant.

January 21, 2015

With specialty and biotech drugs claiming an ever-greater share of the pharmaceutical market and spawning a backlash from payers and patients over their high price tags, pharmacy operators are smack in the middle of a growing tug of war between the drug industry, the public and private health plans struggling to keep up with the new drug-cost paradigm.

January 7, 2015

The pharmaceutical industry is back. Fueled by the launch of expensive, new biotech medicines, rising prices for both branded and generic drugs and a recent slowdown in branded-drug patent expirations and generic competition, the U.S. pharmaceutical market is staging a remarkable resurgence.

December 22, 2014

Mylan has announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day (twice weekly), which is the generic version of Novartis' Vivelle-DOT.

December 1, 2014

November front-end drug store sales are expected to be comparable to last year while prescriptions dispensed will be up in the low single-digit range, reported Ed Kelly, Credit Suisse research analyst.

 

November 20, 2014

More specialty drug innovation, greater patient access to medicines and reduced impact from patent expiries will be the primary drivers of an increase in global medicine spending of up to 30% by 2018.

November 10, 2014

Sandoz last week announced the launch of a generic version of cyclophosphamide injection, USP. Sandoz is launching the drug through collaboration with Jiangsu Hengrui Medicine Co., which owns the product's abbreviated new drug application. 

October 10, 2014

The Drug Enforcement Administration’s final rule moving hydrocodone combination products from Schedule III to the more-restrictive Schedule II officially went into effect on Monday. 

September 11, 2014

Par Pharmaceutical Cos. earlier this week resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL, the generic form of Hospira's Precedex injection. 

September 10, 2014

Mylan announced that its subsidiary, Mylan Ireland Limited, has agreed to acquire the U.S. rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic version of Arixtra from Aspen Global. 

September 5, 2014

Mylan on Friday announced that it has launched a generic version of Hoffmann-La Roche's Boniva injection.

August 24, 2014

IMS Health VP industry relations Doug Long briefed a packed house of NACDS TSE attendees on the latest trends shaping the U.S. pharmaceutical market.

August 24, 2014

IMS Health VP global supply services Hossam Sadek presented the IMS Health Bernie Greenberg Pharmacy Partnership Award to Walgreens group VP pharmaceutical development, Gerry Gleeson, during an Insight Session Sunday morning.

August 20, 2014

Pfizer successfully switched Nexium to over-the-counter in late May, and with that brought a $6 billion book of prescription business to antacid aisles, according to IMS Health data compiled over 2012.

July 10, 2014

As lifetime earnings for pharmaceuticals decrease, commercialization expenses increase and payers tighten their belts on reimbursement, life science companies will be faced with shrinking margins over the next few years. In order to maintain basic operating margin levels and continue investing in research and development at current levels, life science manufacturers will be forced to reduce costs by more than $35 billion by 2017, according to results from a new survey of 70 life science organizations from the IMS Institute for Healthcare Informatics.

June 24, 2014

As Walgreens carefully considers how to best execute the second step of its acquisition of Alliance Boots, Walgreens on Tuesday relayed its progress in improving its domestic business, including the company's success in winning the prescription business of high-value seniors and the pending national launch of its Boots No7 beauty brand.